Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome With Moderate-to-Severe Symptom State (HZNP-DAZ-303)

Next Previous
Trial Profile

A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome With Moderate-to-Severe Symptom State (HZNP-DAZ-303)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Nov 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dazodalibep (Primary)
  • Indications Sjogren's syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms OASIZ 303; OASIZ-303
  • Sponsors Amgen

Most Recent Events

  • 22 Sep 2026 According to Amgen media release, the trial is expected to complete in Q4 2026.
  • 21 Sep 2026 This trial has been completed in Belgium, Spain, Denmark, Slovenia, Hungary, Portugal, Germany, Italy, Croatia, Greece, France, Poland ,as per Clinical Trials Information System record.
  • 08 Jan 2026 Planned End Date changed from 3 Nov 2026 to 17 Dec 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top